Kyverna Therapeutics, Inc.
KYTX
$2.28
$0.062.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -127.48M | -110.66M | -76.16M | -47.36M | -31.81M |
| Total Depreciation and Amortization | 2.13M | 2.03M | 1.47M | 944.00K | 856.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.24M | 4.04M | 2.85M | 3.16M | 1.41M |
| Change in Net Operating Assets | 7.86M | 8.83M | 3.58M | -829.00K | -474.00K |
| Cash from Operations | -114.25M | -95.75M | -79.40M | -55.22M | -41.15M |
| Capital Expenditure | -2.21M | -2.01M | -1.91M | -877.00K | -362.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -158.70M | -156.44M | -157.21M | -90.32M | 45.70M |
| Cash from Investing | -160.90M | -158.44M | -213.24M | -145.32M | -8.78M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -956.00K | -928.00K | -686.00K | -450.00K | -387.00K |
| Issuance of Common Stock | 341.43M | 341.67M | 341.58M | 341.51M | 299.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.36M | -4.85M | -4.85M | -4.45M | -1.49M |
| Cash from Financing | 337.11M | 335.89M | 370.84M | 371.41M | 33.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 61.96M | 81.70M | 78.20M | 170.87M | -16.72M |